


ST 198

Cat. No.:	HY-111280
CAS No.:	854924-64-4
Molecular Formula:	C ₂₂ H ₂₆ N ₂ O
Molecular Weight:	334.45
Target:	Dopamine Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ST 198 is an orally active D3R antagonist. ST 198 can block the expression of nicotine-induced CPP at doses selective for D3R. ST 198 can be used for the research of neurological disease ^[1] .								
In Vitro	ST 198 can block the expression of nicotine-induced CPP at doses selective for D3R ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	ST 198 (p.o.; 3, 30, 100 mg/kg) inhibits the expression of nicotine CPPs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Rats^[1].</td> </tr> <tr> <td>Dosage:</td> <td>3, 30, 100 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o</td> </tr> <tr> <td>Result:</td> <td>Displayed nicotine-induced CPP.</td> </tr> </table>	Animal Model:	Rats ^[1] .	Dosage:	3, 30, 100 mg/kg	Administration:	p.o	Result:	Displayed nicotine-induced CPP.
Animal Model:	Rats ^[1] .								
Dosage:	3, 30, 100 mg/kg								
Administration:	p.o								
Result:	Displayed nicotine-induced CPP.								

REFERENCES

[1]. Le Foll B, et al. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. *Neuropsychopharmacology*. 2005;30(4):720-730.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA